These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 28482067)

  • 1. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
    Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
    Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
    Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
    J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic characterization and mutational profiling of foramen magnum meningiomas: a multi-institutional study.
    Hua L; Alkhatib M; Fujio S; Alhasan B; Herold S; Zeugner S; Zolal A; Hijazi MM; Clark VE; Wakimoto H; Shankar GM; Brastianos PK; Barker FG; Cahill DP; Ren L; Eyüpoglu IY; Gong Y; Schackert G; Juratli TA
    J Neurosurg; 2024 Jul; 141(1):72-78. PubMed ID: 38277657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic landscape of meningioma.
    Yuzawa S; Nishihara H; Tanaka S
    Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry.
    Sahm F; Bissel J; Koelsche C; Schweizer L; Capper D; Reuss D; Böhmer K; Lass U; Göck T; Kalis K; Meyer J; Habel A; Brehmer S; Mittelbronn M; Jones DT; Schittenhelm J; Urbschat S; Ketter R; Heim S; Mawrin C; Hainfellner JA; Berghoff AS; Preusser M; Becker A; Herold-Mende C; Unterberg A; Hartmann C; Kickingereder P; Collins VP; Pfister SM; von Deimling A
    Acta Neuropathol; 2013 Nov; 126(5):757-62. PubMed ID: 24096618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KLF4
    von Spreckelsen N; Waldt N; Poetschke R; Kesseler C; Dohmen H; Jiao HK; Nemeth A; Schob S; Scherlach C; Sandalcioglu IE; Deckert M; Angenstein F; Krischek B; Stavrinou P; Timmer M; Remke M; Kirches E; Goldbrunner R; Chiocca EA; Huettelmaier S; Acker T; Mawrin C
    Acta Neuropathol Commun; 2020 Apr; 8(1):41. PubMed ID: 32245394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
    Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M
    Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative treatments for meningiomas.
    Graillon T; Tabouret E; Salgues B; Horowitz T; Padovani L; Appay R; Farah K; Dufour H; Régis J; Guedj E; Barlier A; Chinot O
    Rev Neurol (Paris); 2023 Jun; 179(5):449-463. PubMed ID: 36959063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
    Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
    Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
    Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
    Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
    Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
    Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.
    El-Habr EA; Levidou G; Trigka EA; Sakalidou J; Piperi C; Chatziandreou I; Spyropoulou A; Soldatos R; Tomara G; Petraki K; Samaras V; Zisakis A; Varsos V; Vrettakos G; Boviatsis E; Patsouris E; Saetta AA; Korkolopoulou P
    Virchows Arch; 2014 Oct; 465(4):473-85. PubMed ID: 25146167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
    Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
    Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WHO grade, proliferation index, and progesterone receptor expression are different according to the location of meningioma.
    Maiuri F; Mariniello G; Guadagno E; Barbato M; Corvino S; Del Basso De Caro M
    Acta Neurochir (Wien); 2019 Dec; 161(12):2553-2561. PubMed ID: 31637512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway.
    Johnson MD; O'Connell MJ; Pilcher W; Reeder JE
    J Neurosurg; 2010 May; 112(5):934-9. PubMed ID: 19698046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
    Reuss DE; Piro RM; Jones DT; Simon M; Ketter R; Kool M; Becker A; Sahm F; Pusch S; Meyer J; Hagenlocher C; Schweizer L; Capper D; Kickingereder P; Mucha J; Koelsche C; Jäger N; Santarius T; Tarpey PS; Stephens PJ; Andrew Futreal P; Wellenreuther R; Kraus J; Lenartz D; Herold-Mende C; Hartmann C; Mawrin C; Giese N; Eils R; Collins VP; König R; Wiestler OD; Pfister SM; von Deimling A
    Acta Neuropathol; 2013 Mar; 125(3):351-8. PubMed ID: 23404370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progesterone Receptor Is Responsible for Benign Biology of Skull Base Meningioma.
    Kuroi Y; Matsumoto K; Shibuya M; Kasuya H
    World Neurosurg; 2018 Oct; 118():e918-e924. PubMed ID: 30031954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas.
    Strickland MR; Gill CM; Nayyar N; D'Andrea MR; Thiede C; Juratli TA; Schackert G; Borger DR; Santagata S; Frosch MP; Cahill DP; Brastianos PK; Barker FG
    J Neurosurg; 2017 Aug; 127(2):438-444. PubMed ID: 27885953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
    Mawrin C; Sasse T; Kirches E; Kropf S; Schneider T; Grimm C; Pambor C; Vorwerk CK; Firsching R; Lendeckel U; Dietzmann K
    Clin Cancer Res; 2005 Jun; 11(11):4074-82. PubMed ID: 15930342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.